Peptide Synthesis Market

Publisher Roots Analysis

Published Feb 01, 2024

Length 390 Pages

SKU # ROAL18576020

Description

Peptide Synthesis Market

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)The peptide synthesis market is expected to reach USD 2.5 billion by 2023 anticipated to grow at a CAGR of 5.46% during the forecast period 2023-2035.

Peptides function as signaling molecules that bind to specific receptors on cell surfaces, initiating intracellular effects that regulate physiological functions and metabolic synthesis of various components. Their significance as potential therapeutics has increased due to improved metabolic stability, target specificity, and affinity. Unlike small molecule drugs and biologics, peptide-based therapeutics pose unique challenges in pharmacological research, analytical/process development, impurity research, and structure recognition. The peptide synthesis market has undergone significant evolution recently, driven by the rising popularity of peptide therapeutics. Currently, more than 80 peptide therapeutics have received global approval for treating various chronic diseases such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. Additionally, since 2015, over 630 clinical trials have been conducted to assess the therapeutic efficacy of peptide-based therapies. Furthermore, increased research activity and demand for peptide-based treatments have prompted developers to enhance their capabilities and upgrade manufacturing equipment. However, peptide synthesis encounters challenges such as production capacity shortages, leading developers to outsource complex manufacturing processes to contract service providers to reduce costs and time to market. Pharmaceutical and biotechnology firms are actively partnering with contract manufacturing organizations (CMOs) offering advanced technology platforms to improve the bioavailability of peptide drugs and enhance synthesis efficacy. The demand for outsourcing surged with the introduction of semaglutide generics into the peptide synthesis market. Notably, the demand for GLP-1 peptide API contract manufacturing increased significantly at an annual rate of 37% during 2017-2023 due to its benefits in treating metabolic disorders like type II diabetes and obesity. These factors present promising opportunities for contract manufacturers in the peptide synthesis market in the foreseeable future.Report Coverage

The report comprehensively examines the peptide synthesis market based on type of synthesis method used, type of chemical synthesis method, company (CMO) size and key geographical regions.

It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.

An extensive assessment of the current market landscape of contract manufacturers offering peptide synthesis services, covering various relevant parameters such as establishment year, entry year into peptide API manufacturing, company size (employee count), headquarters location, product type (API, intermediates, FDF / fill-finish), API type, services provided, peptide synthesis method, peptide modification type, purification technology, regulatory certifications, geographical presence, and location of peptide API manufacturing facilities.

Detailed evaluation of the competitiveness of peptide synthesis contract manufacturers, considering supplier strength and company competitiveness regarding API type, service offering, synthesis method, purification technique, operational scale, and geographical presence. Additionally, the number of peptide modification services offered is also taken into account. This evaluation includes a comprehensive review of recent developments and initiatives undertaken by contract manufacturers in the peptide synthesis industry, focusing on partnerships, collaborations, and expansion initiatives from 2014 to October 2023.

In-depth analysis of ongoing and planned studies focused on peptide therapeutics, covering various parameters such as trial registration year, number of enrolled patients, trial phase, status, study design, sponsor/collaborator type, therapeutic area, mechanism of action, clinical trial centers, geography, and patient population.

Detailed examination of the capabilities of peptide synthesis companies in different regions, considering parameters like the number of Contract Manufacturing Organizations (CMOs), clinical sites, clinical trials, enrolled patients, peptide manufacturing facilities, demand for peptide therapeutics, and installed capacity.

Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on parameters such as target patient population, dosing frequency, and dose strength.

Estimate of the global installed capacity of contract manufacturers in the peptide synthesis market, considering data reported by industry stakeholders and factoring in the distribution of peptide production capacity among companies of different sizes (small, mid-sized, and large), operational scale (preclinical/clinical and commercial), location of manufacturing facility (North America, Europe, and Asia Pacific), and synthesis method (solid phase peptide synthesis and liquid phase peptide synthesis).

Analysis highlighting potential strategic partners based on the likelihood of collaborating with peptide therapeutics developers, shortlisted considering parameters like pipeline strength, pipeline maturity, year of establishment, and company size.

Qualitative examination outlining the key factors that peptide drug developers must consider when deciding whether to produce their products in-house or engage the services of a Contract Manufacturing Organization (CMO).

In-depth, region-specific analysis of the total cost of ownership associated with engaging a peptide contract manufacturing service provider, providing an estimate of both direct and indirect expenses across 10 relevant parameters over a 20-year timeframe.

Review of regulatory guidelines concerning peptide synthesis, focusing on variations observed across different regions such as the US, Europe, Australia, China, India, Japan, and South Korea. This discussion also addresses the regulatory challenges faced by peptide synthesis companies.

Discussion on industry-related trends, key drivers, and challenges within the peptide synthesis sector, structured within a SWOT framework, including a Harvey ball assessment to highlight the relative impact of each SWOT parameter on industry dynamics.

Key Market Companies

AmbioPharm

CPC Scientific

Creative Peptides

CSBio

Bachem

BCN Peptide

CordenPharma

Senn Chemicals

PolyPeptide

Auspep

Chinese Peptide Company

Hybio Pharmaceuticals

Peptide Institute

ScinoPharm

1. Preface: 1.1. Introduction; 1.2. Market Share Insights; 1.3. Key Market Insights; 1.4. Report Coverage; 1.5. Key Questions Answered; 1.6. Chapter Outlines
2. Research Methodology: 2.1. Chapter Overview; 2.2. Research Assumptions; 2.3. Project Methodology; 2.4. Forecast Methodology; 2.5. Robust Quality Control; 2.6. Key Considerations; 2.6.1. Demographics; 2.6.2. Economic Factors; 2.6.3. Government Regulations; 2.6.4. Supply Chain; 2.6.5. Covid Impact / Related Factors; 2.6.6. Market Access; 2.6.7. Healthcare Policies; 2.6.8. Industry Consolidation; 2.7. Key Market Segmentations
3. Economic And Other Project Specific Considerations: 3.1. Chapter Overview; 3.2. Market Dynamics; 3.2.1. Time Period; 3.2.1.1. Historical Trends; 3.2.1.2. Current And Forecasted Estimates; 3.2.2. Currency Coverage; 3.2.2.1. Overview Of Major Currencies Affecting The Market; 3.2.2.2. Impact Of Currency Fluctuations On The Industry; 3.2.3. Foreign Exchange Impact; 3.2.3.1. Evaluation Of Foreign Exchange Rates And Their Impact On Market; 3.2.3.2. Strategies For Mitigating Foreign Exchange Risk; 3.2.4. Recession; 3.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt; 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market; 3.2.5. Inflation; 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy; 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
4. Executive Summary
5. Introduction: 5.1. Chapter Overview; 5.2. Overview Of Peptides; 5.2.1. Structural Analysis Of Peptides; 5.2.2. Classification Of Peptides; 5.2.3. Peptide Synthesis; 5.2.4. Emerging Technologies For Peptide Synthesis; 5.2.5. Peptide Modification; 5.2.5.1. N-terminal Modification; 5.2.5.2. Internal Modification; 5.2.5.3. C-terminal Modification; 5.2.5.4. Other Modifications; 5.2.6. Peptide Purification; 5.2.6.1. Peptide Purity Guidelines; 5.3. Overview Of Contract Manufacturing; 5.3.1. Need For Outsourcing In The Peptide Manufacturing Industry; 5.3.2. General Considerations For Selecting A Cmo Partner; 5.3.3. Advantages Of Outsourcing Manufacturing Operations; 5.3.4. Risks And Challenges Associated With Outsourcing Of Peptide Api Manufacturing; 5.4. Future Perspectives
6. Regulatory Landscape: 6.1. Chapter Overview; 6.2. Regulatory Scenario: North America; 6.2.1. Scenario In The Us; 6.2.1.1. Overview; 6.2.1.2. General Guidelines For Peptide Manufacturing; 6.3. Regulatory Scenario: Europe; 6.3.1. Scenario In Europe; 6.3.1.1. Overview; 6.3.1.2. General Guidelines; 6.3.2. Scenario In The Uk; 6.3.2.1. Overview; 6.3.2.2. General Guidelines For Peptide Manufacturing; 6.4. Regulatory Scenario: Asia-pacific; 6.4.1. Overview; 6.4.2. Scenario In Australian; 6.4.2.1. General Guidelines For Peptide Manufacturing; 6.4.3. Scenario In Chinese; 6.4.3.1. General Guidelines For Peptide Manufacturing; 6.4.3.2. Tax-related Modifications In Chinese Pharmaceutical Sector; 6.4.4. Scenario In India; 6.4.4.1. General Guidelines For Peptide Manufacturing; 6.4.4.2. Tax-related Modifications In Indian Pharmaceutical Sector; 6.4.5. Scenario In Japan; 6.4.5.1. General Guidelines For Peptide Manufacturing; 6.4.6. Scenario In South Korea; 6.4.6.1. General Guidelines For Peptide Manufacturing; 6.5. Challenges Associated With Peptide Manufacturing
7. Market Landscape: 7.1 Chapter Overview; 7.2 Peptide Therapeutics Contract Api Manufacturing: Overall Market Landscape; 7.2.1. Analysis By Year Of Establishment; 7.2.2. Analysis By Year Of Entrance Of Peptide Api Contract Manufacturers; 7.2.3. Analysis By Company Size; 7.2.4. Analysis By Location Of Headquarters; 7.2.5. Analysis By Type Of Product; 7.2.6. Analysis By Type Of Api Manufactured; 7.2.7. Analysis By Scale Of Operation; 7.2.8. Analysis By Type Of Services Offered; 7.2.9. Analysis By Type Of Peptide Synthesis Method; 7.2.10. Analysis By Type Of Peptide Modification; 7.2.11. Analysis By Type Of Purification Technology Used; 7.2.12. Analysis By Regulatory Certifications And Accreditations; 7.2.13. Analysis By Geographical Presence; 7.2.14. Analysis By Location Of Peptide Api Manufacturing Facilities; 7.3. List Of Custom Peptide Manufacturers
8. Company Competitivenss Analysis: 8.1. Chapter Overview; 8.2. Key Parameters; 8.3. Methodology; 8.4. Company Competitiveness Analysis; 8.4.1 Peptide Therapeutics Contract Api Manufacturers With Low Manufacturing Capacity; 8.4.2 Peptide Therapeutics Contract Api Manufacturers With Medium Manufacturing Capacity; 8.4.2 Peptide Therapeutics Contract Api Manufacturers With High Manufacturing Capacity
9. Company Profiles: 9.1 Chapter Overview; 9.2. Peptide Therapeutics Contract Api Manufacturers Based In North America; 9.2.1. Ambiopharm; 9.2.1.1. Company Overview; 9.2.1.2. Service Portfolio; 9.2.1.3. Manufacturing Facilities And Capabilities; 9.2.1.4. Recent Developments And Future Outlook; 9.2.2. Cpc Scientific; 9.2.2.1. Company Overview; 9.2.2.2. Service Portfolio; 9.2.2.3. Manufacturing Facilities And Capabilities; 9.2.2.4. Recent Developments And Future Outlook; 9.2.3. Creative Peptides; 9.2.3.1. Company Overview; 9.2.3.2. Service Portfolio; 9.2.3.3. Manufacturing Facilities And Capabilities; 9.2.3.4. Recent Developments And Future Outlook; 9.2.4. Csbio; 9.2.4.1. Company Overview; 9.2.4.2. Service Portfolio; 9.2.4.3. Manufacturing Facilities Andcapabilities; 9.2.4.4. Recent Developments And Future Outlook; 9.3. Peptide Therapeutics Contract Api Manufacturers Based In Europe; 9.3.1. Bachem; 9.3.1.1. Company Overview; 9.3.1.2. Service Portfolio; 9.3.1.3. Manufacturing Facility And Capabilities; 9.3.1.4. Recent Developments And Future Outlook; 9.3.2. Bcn Peptides; 9.3.2.1. Company Overview; 9.3.2.2. Service Portfolio; 9.3.2.3. Manufacturing Facility Andcapabilities; 9.3.2.4. Recent Development And Future Outlook; 9.3.3. Cordenpharma; 9.3.3.1. Company Overview; 9.3.3.2. Service Portfolio; 9.3.3.3. Manufacturing Facility And Capabilities; 9.3.3.4. Recent Developments And Future Outlook; 9.3.4. Polypeptide; 9.3.4.1. Company Overview; 9.3.4.2. Service Portfolio; 9.3.4.3. Manufacturing Facilities And Capabilities; 9.3.4.4. Recent Developments And Future Outlook; 9.3.5. Senn Chemicals; 9.3.5.1. Company Overview; 9.3.5.2. Service Portfolio; 9.3.5.3. Manufacturing Facilities And Capabilities; 9.3.5.4. Recent Developments And Future Outlook; 9.4. Peptide Therapeutics Contract Api Manufacturers Based In Asia-pacific; 9.4.1. Auspep; 9.4.1.1. Company Overview; 9.4.1.2. Service Portfolio; 9.4.1.3. Manufacturing Facilities And Capabilities; 9.4.1.4. Recent Developments And Future Outlook; 9.4.2. Chinese Peptide; 9.4.2.1. Company Overview; 9.4.2.2. Service Portfolio; 9.4.2.3. Manufacturing Facilities And Capabilities; 9.4.2.4. Recent Developments And Future Outlook; 9.4.3. Hybio Pharmaceutical; 9.4.3.1. Company Overview; 9.4.3.2. Service Portfolio; 9.4.3.3. Manufacturing Facilities And Capabilities; 9.4.3.4. Recent Developments And Future Outlook; 9.4.4. Peptide Institute; 9.4.4.1. Company Overview; 9.4.4.2. Service Portfolio; 9.4.4.3. Manufacturing Facilities And Capabilities; 9.4.4.4. Recent Developments And Future Outlook; 9.4.5. Scinopharm; 9.4.5.1. Company Overview; 9.4.5.2. Service Portfolio; 9.4.5.3. Manufacturing Facilities And Capabilities; 9.4.5.4. Recent Developments And Future Outlook
10. Recent Developments And Initiatives: 10.1. Chapter Overview; 10.2. Partnerships And Collaborations; 10.2.1. Partnerships Models; 10.2.2. List Of Partnerships And Collaborations; 10.2.3. Analysis By Year Of Partnership; 10.2.4. Analysis By Type Of Partnership; 10.2.5. Analysis By Year And Type Of Partnership; 10.2.6. Analysis By Company Size And Type Of Partnership; 10.2.7. Analysis By Scale Of Operation; 10.2.8. Analysis By Scale Of Operation And Type Of Partnership; 10.2.9. Analysis By Green Chemistry Integration; 10.2.10. Most Active Players: Analysis By Number Of Partnerships; 10.2.11. Analysis By Geography; 10.2.11.1. Intercontinental And Intracontinental Agreements; 10.2.12.2. Local And International Agreements; 10.3. Recent Expansion Models; 10.3.1. Expansion Models; 10.3.2 List Of Recent Expansions; 10.3.3. Analysis By Year Of Expansion; 10.3.4. Analysis By Type Of Expansion; 10.3.5. Analysis By Year And Type Of Expansion; 10.3.6. Analysis By Location Of Expanded Facility (Region); 10.3.7. Analysis By Location Of Expanded Facility (Country); 10.3.8. Recent Expansions: Analysis By Location Of Expanded Facility And Type Of Expansion; 10.3.9. Most Active Players: Analysis By Number Of Expansions; 10.3.10. Recent Expansions: Analysis By Geography (Country); 10.3.11. Recent Expansions: List Of Planned Expansions; 10.4. Emerging Peptide Synthesis Technologies; 10.4.1. Chemo-enzymatic Peptide Synthesis Technology; 10.4.2. Continuous Flow Technology; 10.4.3. Green Chemistry
11. Clinical Trial Analysis: 11.1. Chapter Overview; 11.2. Scope And Methodology; 11.3. Peptide Therapeutics: Clinical Trials Analysis; 11.3.1. Analysis By Trial Registration Year; 11.3.2. Analysis By Number Of Patients Enrolled; 11.3.3. Analysis By Trial Phase; 11.3.4. Analysis By Trial Registration Year And Trial Phase; 11.3.5. Analysis By Trial Phase And Patients Enrolled; 11.3.6. Analysis By Trial Status; 11.3.7. Analysis By Trial Registration Year And Trial Status; 11.3.8. Analysis By Therapeutic Area; 11.3.9. Analysis By Mechanism Of Action; 11.3.10. Analysis By Trial Registration Year And Mechanism Of Action; 11.3.11. Analysis By Type Of Sponsor / Collaborator; 11.3.12. Analysis By Study Design; 11.3.12.1. Analysis By Type Of Patient Allocation Model Used; 11.3.12.2. Analysis By Type Of Trial Masking Adopted; 11.3.12.3. Analysis By Type Of Intervention; 11.3.12.4. Analysis By Trial Purpose; 11.3.13. Most Active Players: Analysis By Number Of Clinical Trials; 11.3.14. Analysis By Geography; 11.3.14.1. Analysis Of Clinical Trials By Geography; 11.3.14.2. Analysis Of Clinical Trials By Geography And Trial Status; 11.3.14.3. Analysis Of Clinical Trials By Geography And Therapeutic Area; 11.3.14.4. Analysis Of Patients Enrolled By Geography; 11.3.14.5. Analysis Of Patients Enrolled By Geography And Trial Status
12. Regional Capability Analysis: 12.1. Chapter Overview; 12.2. Key Assumptions And Methodology; 12.3. Overall Landscape Of Peptide Therapeutics Contract Api Manufacturing Facilities; 12.4. Peptide Therapeutics Contract Api Manufacturing Capability In North America; 12.5. Peptide Therapeutics Contract Api Manufacturing Capability In Europe; 12.6. Peptide Therapeutics Contract Api Manufacturing Capability In Asia-pacific
13. Demand Analysis: 13.1. Chapter Overview; 13.2. Assumptions And Methodology; 13.3. Peptide Therapeutics Contract Api Manufacturing: Overall Annual Demand; 13.3.1. Peptide Therapeutics Contract Api Manufacturing: Clinical Demand; 13.3.1.1. Clinical Demand For Peptide Therapeutics Contract Api Manufacturing: Analysis By Phase Of Development; 13.3.2. Peptide Therapeutics Contract Api Manufacturing: Commercial Outsourced Demand; 13.3.2.1. Commercial Demand For Peptide Therapeutics Contract Api Manufacturing: Analysis By Glp-1 Mechanism Of Action; 13.3.3. Peptide Therapeutics Contract Api Manufacturing: Analysis By Type Of Peptide Api Synthesis; 13.3.4. Peptide Therapeutics Contract Api Manufacturing: Analysis By Geography
14. Capacity Analysis: 14.1. Chapter Overview; 14.2. Key Assumptions And Methodology; 14.3. Peptide Therapeutics Contract Api Manufacturing: Global Installed Capacity; 14.3.1. Analysis By Company Size; 14.3.2. Analysis By Scale Of Operation; 14.3.3. Analysis By Location Of Manufacturing Facility; 14.3.4. Analysis By Company Size And Location Of Manufacturing Facility; 14.3.5 Analysis By Chemical Synthesis Method; 14.4. Concluding Remarks
15. Likely Partners Anlaysis: 15.1. Chapter Overview; 15.2. Scoring Criteria And Key Assumptions; 15.3. Scope And Methodology; 15.4. Potential Strategic Partners For Peptide Therapeutics Contract Manufacturers In North America; 15.4.1. Most Likely Partners; 15.4.2. Likely Partners; 15.4.3. Least Likely Partners; 15.5. Potential Strategic Partners For Peptide Therapeutics Contract Manufacturers In Europe; 15.5.1. Most Likely Partners; 15.5.2. Likely Partners; 15.5.3. Least Likely Partners; 15.6. Potential Strategic Partners For Peptide Therapeutics Contract Manufacturers In Asia Pacific And Rest Of The World; 15.6.1. Most Likely Partners; 15.6.2. Likely Partners; 15.6.3. Least Likely Partners
16. Make Versus Buy Decision Making Framework: 16.1. Chapter Overview; 16.2. Assumptions And Parameter Definitions; 16.3. Make Versus Buy Decision Making Framework; 16.3.1. Scenario 1; 16.3.2. Scenario 2; 16.3.3. Scenario 3; 16.3.4. Scenario 4; 16.4. Concluding Remarks
17. Total Cost Of Ownership For Peptide Contract Manufacturing Organizations: 17.1. Chapter Overview; 17.2. Assumptions And Methodology; 17.3. Key Parameters; 17.4. Total Cost Of Ownership For Peptide Therapeutics Contract Api Manufacturing Organization, Y0-y20; 17.5. Total Cost Of Ownership For Peptide Therapeutics Contract Api Manufacturing Organization: Analysis By Capex And Opex, Y0 And Y20; 17.5.1. Total Cost Of Ownership For Peptide Therapeutics Contract Api Manufacturing Organization: Analysis By Capex, Y0; 17.5.2. Total Cost Of Ownership For Peptide Therapeutics Contract Api Manufacturing Organization: Analysis By Opex, Y1-y20
18. Global Peptide Therapeutics Contract Api Manufacturing Market: 18.1. Chapter Overview; 18.2. Key Assumptions And Methodology; 18.3. Global Peptide Therapeutics Contract Api Manufacturing Market, Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 18.3.1. Scenario Analysis; 18.3.1.1. Conservative Scenario; 18.3.1.2. Optimistic Scenario; 18.4. Key Market Segmentations
19. Peptide Therapeutics Contract Api Manufacturing Market, By Type Of Peptide Synthesis Method: 19.1. Chapter Overview; 19.2. Key Assumptions And Methodology; 19.3. Peptide Therapeutics Contract Api Manufacturing Market: Distribution By Type Of Peptide Synthesis Method, 2023 And 2035; 19.3.1. Non-chemical Synthesis Method Market: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 19.3.2. Chemical Synthesis Method Market: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 19.3.2.1 Liquid Phase Synthesis: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 19.3.2.2 Solid Phase Synthesis: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 19.3.2.3 Hybrid Phase Synthesis: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 19.4. Data Triangulation And Validation
20. Peptide Therapeutics Contract Api Manufacturing Market, By Company Size: 20.1. Chapter Overview; 20.2. Key Assumptions And Methodology; 20.3. Peptide Therapeutics Contract Api Manufacturing Market: Distribution By Company Size, 2023 And 2035; 20.3.1. Small Company: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 20.3.2. Mid-sized Company: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 20.3.3. Large Company: Historical Trends (2021-2023) And Forecasted Estimates (2024-2035); 20.4. Data Triangulation And Validation
21. Peptide Therapeutics Contract Api Manufacturing Market, By Geography: 21.1. Chapter Overview; 21.2. Assumptions And Methodology; 21.3. Peptide Therapeutics Contract Api Manufacturing Market: Distribution By Geography, 2024 And 2035; 21.3.1. Peptide Therapeutics Contract Api Manufacturing Market In North America: Historical Trends (2021-2024) And Forecasted Estimates (2024-2035); 21.3.1.1. Peptide Therapeutics Contract Api Manufacturing Market For Small Companies In North America; 21.3.1.2. Peptide Therapeutics Contract Api Manufacturing Market For Mid-sized Companies In North America; 21.3.1.3. Peptide Therapeutics Contract Api Manufacturing Market For Large And Very Large Companies In North America; 21.3.1.4. Peptide Therapeutics Contract Api Manufacturing Market In North America For Chemical Synthesis Method; 21.3.1.5. Peptide Therapeutics Contract Api Manufacturing Market In North America For Non-chemical Synthesis Method; 21.3.2. Peptide Therapeutics Contract Api Manufacturing Market In Europe: Historical Trends (2021-2024) And Forecasted Estimates (2024-2035); 21.3.2.1. Peptide Therapeutics Contract Api Manufacturing Market For Small Companies In Europe; 21.3.2.2. Peptide Therapeutics Contract Api Manufacturing Market For Mid-sized Companies In Europe; 21.3.2.3. Peptide Therapeutics Contract Api Manufacturing Market For Large And Very Large Companies In Europe; 21.3.2.4. Peptide Therapeutics Contract Api Manufacturing Market In Europe For Chemical Synthesis Method; 21.3.2.5. Peptide Therapeutics Contract Api Manufacturing Market In Europe For Non-chemical Synthesis Method; 21.3.3. Peptide Therapeutics Contract Api Manufacturing Market In Asia-pacific And Rest Of The World: Historical Trends (2021-2024) And Forecasted Estimates (2024-2035); 21.3.3.1. Peptide Therapeutics Contract Api Manufacturing Market For Small Companies In Asia-pacific And Rest Of The World; 21.3.3.2. Peptide Therapeutics Contract Api Manufacturing Market For Mid-sized Companies In Asia-pacific And Rest Of The World; 21.3.3.3. Peptide Therapeutics Contract Api Manufacturing Market For Large And Very Large Companies In Asia-pacific And Rest Of The World; 21.3.3.4. Peptide Therapeutics Contract Api Manufacturing Market In Asia-pacific And Rest Of The World For Chemical Synthesis Method; 21.3.3.5. Peptide Therapeutics Contract Api Manufacturing Market In Asia-pacific And Rest Of The World For Non-chemical Synthesis Method; 21.4. Data Triangulation And Validation
22. Swot Analysis: 22.1. Chapter Overview; 22.2. Strengths; 22.3. Weaknesses; 22.4. Opportunities; 22.5. Threats; 22.6. Comparison Of Swot Factors; 22.7. Concluding Remarks
23. Conclusion
24. Executive Insights: 24.1. Chapter Overview; 24.2. Ascendia Pharmaceuticals; 24.2.1 Company Snapshot; 24.2.2. Interview Transcript: Robert Bloder (Chief Business Officer), Shaukat Ali (Senior Director Of Scientific Affairs And Technical Marketing); 24.3. Almac; 24.3.1 Company Snapshot; 24.3.2. Interview Transcript: Alastair Hay (Vice President, Peptides); 24.4. Numaferm; 24.4.1 Company Snapshot; 24.4.2. Interview Transcript: Philipp Burling (Chief Financial Officer); 24.5. Sekisui Xenotech; 24.5.1 Company Snapshot; 24.5.2. Interview Transcript: Hideki Kubota (Senior Manager, Peptide Business Project Leader); 24.6. Previtalica; 24.6.1 Company Snapshot; 24.6.2. Interview Transcript: Sergiy Stupka (Founder And Owner)
25. Appendix I: Tabulated Data
26. Appendix Ii: List Of Companies And Organizations

Pricing

Currency Rates

PDF Email from Publisher – One User License $4,799
PDF Email from Publisher – Consulting Company Team License $8,999
PDF Email from Publisher – Department License $10,599
PDF Email from Publisher – Global Site License for One Company $17,999

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now